ANI Pharmaceuticals Proposes $560 Million Egetis Therapeutics Deal

ANI’s $560 million offer for Egetis adds EMCITATE, a treatment for ultra-rare MCT8 deficiency, with peak annual sales estimated above $300 million and protection into 2045.